Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 76 |
| Active Pipeline (Recruiting Now) | 29 (17) |
| Completed vs Stopped Early | 21 / 3 (4.0%) |
| Median Closed Actual Enrollment | 39 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Seoul National University Hospital | Seoul | 59 |
| Seoul National University Bundang Hospital | Seongnam-si, Gyeonggi-do | 6 |
| Severance Hospital | Seoul, Seoul,50-1 Yonsei-ro/Seodaemun-gu | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05534087 | Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12) | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Seoul National University Hospital Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.